Prophylactic Mitigation of Acute Graft versus Host Disease by Novel 2-(Pyrrolidin-1-ylmethyl)pyrrole-Based Stimulation-2 (ST2) Inhibitors.

Hematopoietic cell transplantation (HCT) is a proven and potentially curable therapy for hematological malignancies and inherited hematological disease. The main risk of HCT is the development of graft versus host disease (GVHD) acquired in up to 50% of patients. Upregulation of soluble ST2 (sST2) is a key clinical biomarker for GVHD prognosis and was shown to be a potential therapeutic target for GVHD. Agents targeting sST2 to reduce the sST2 level after HCT have the potential to mitigate GVHD progression. Here, we report 32 (or XY52) as the lead ST2 inhibitor from our optimization campaign. XY52 had improved inhibitory activity and metabolic stability in vitro and in vivo. XY52 suppressed proinflammatory T-cell proliferation while increasing regulatory T cells in vitro. In a clinically relevant GVHD model, a 21-day prophylactic regimen of XY52 reduced plasma sST2 and IFN-γ levels and GVHD score and extended survival in mice. XY52 represented a significant improvement over our previous compound, iST2-1, and further optimization of XY52 is warranted. The small-molecule ST2 inhibitors can potentially be used as a biomarker-guided therapy for mitigating GVHD in future clinical applications.

[1]  I. Pusic,et al.  Acute Graft-versus-Host Disease: An Update on New Treatment Options , 2023, Drugs.

[2]  Chao-yie Yang,et al.  Structure-Activity relationship of 1-(Furan-2ylmethyl)Pyrrolidine-Based Stimulation-2 (ST2) inhibitors for treating graft versus host disease. , 2022, Bioorganic & medicinal chemistry.

[3]  J. A. Spicer,et al.  Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors , 2022, ACS pharmacology & translational science.

[4]  J. Girard,et al.  Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. , 2022, Cytokine.

[5]  M. Toumi,et al.  Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease , 2021, Clinical Drug Investigation.

[6]  Hua Jiang,et al.  T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor , 2021, Frontiers in Immunology.

[7]  J. Ferrara,et al.  New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD) , 2021, Expert opinion on therapeutic targets.

[8]  Xiao Ding,et al.  Small Molecule Approaches to Treat Autoimmune and Inflammatory Diseases (Part III): Targeting Cytokines and Cytokine Receptor Complexes. , 2021, Bioorganic & medicinal chemistry letters.

[9]  N. Kröger,et al.  Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years , 2021, Bone Marrow Transplantation.

[10]  G. Hill,et al.  Current Concepts and Advances in Graft-Versus-Host Disease Immunology. , 2021, Annual review of immunology.

[11]  R. Storb,et al.  History of hematopoietic cell transplantation: challenges and progress , 2020, Haematologica.

[12]  Rongsheng Tong,et al.  Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials , 2020, Signal Transduction and Targeted Therapy.

[13]  C. Hunter,et al.  Cytokine Storms: Understanding COVID-19 , 2020, Immunity.

[14]  J. Dipersio,et al.  Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease , 2020, Therapeutic advances in hematology.

[15]  J. A. Spicer,et al.  Inhibition of the cytolytic protein perforin prevents rejection of transplanted bone marrow stem cells in vivo. , 2020, Journal of medicinal chemistry.

[16]  S. Paczesny.  Post‐haematopoietic cell transplantation outcomes: why ST2 became a ‘golden nugget’ biomarker , 2020, British journal of haematology.

[17]  G. Hill,et al.  Interleukin-10 mediated immune regulation after stem cell transplantation: Mechanisms and implications for therapeutic intervention. , 2019, Seminars in immunology.

[18]  E. Sundberg,et al.  Structural Basis of IL-1 Family Cytokine Signaling , 2019, Front. Immunol..

[19]  Hong Liu,et al.  Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease. , 2019, JCI insight.

[20]  Greg L. Hura,et al.  From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. , 2018, JCI insight.

[21]  Michael U. Martin,et al.  The family of the interleukin‐1 receptors , 2018, Immunological reviews.

[22]  C. Dinarello.  Overview of the IL‐1 family in innate inflammation and acquired immunity , 2018, Immunological reviews.

[23]  T. Maurer,et al.  Relevance of Half-Life in Drug Design. , 2017, Journal of medicinal chemistry.

[24]  T. Wynn,et al.  Type 2 immunity in tissue repair and fibrosis , 2017, Nature Reviews Immunology.

[25]  C. Plass,et al.  Genome-wide DNA methylation landscape defines specialization of regulatory T cells in tissues , 2017, Nature Immunology.

[26]  M. Mohsenzadegan,et al.  The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells , 2017, Cell Communication and Signaling.

[27]  S. Paczesny,et al.  The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases , 2017, Front. Immunol..

[28]  M. A. Abu Zaid,et al.  Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. , 2017, Blood.

[29]  A. Herbelin,et al.  In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis , 2016, The Journal of Immunology.

[30]  Xi Chen,et al.  Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. , 2016, Diabetes research and clinical practice.

[31]  B. Blazar,et al.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? , 2016, Blood.

[32]  H. Hanenberg,et al.  ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease , 2015, Science Translational Medicine.

[33]  R. Locksley,et al.  Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation. , 2015, Immunity.

[34]  G. Hill,et al.  This information is current as Cytokines in Graft-versus-Host Disease , 2015 .

[35]  Thomas A. Wynn,et al.  Type 2 cytokines: mechanisms and therapeutic strategies , 2015, Nature Reviews Immunology.

[36]  Yasmine Belkaid,et al.  The Alarmin IL-33 Promotes Regulatory T Cell Function in the Intestine , 2014, Nature.

[37]  C. Dinarello.  Overview of the interleukin-1 family of ligands and receptors. , 2013, Seminars in immunology.

[38]  M. Iacoviello,et al.  A Novel Cardiac Bio-Marker: ST2: A Review , 2013, Molecules.

[39]  T. Ueland,et al.  Heart failure biomarkers: focus on interleukin-1 receptor-like 1-based blood tests. , 2012, Drugs of today.

[40]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[41]  T. Blundell,et al.  Structural biology and drug discovery of difficult targets: the limits of ligandability. , 2012, Chemistry & biology.

[42]  David Díaz-Jiménez,et al.  Characterization of the novel ST2/IL‐33 system in patients with inflammatory bowel disease , 2010, Inflammatory bowel diseases.

[43]  C. Fiocchi,et al.  Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis , 2010, Proceedings of the National Academy of Sciences.

[44]  A. Sher,et al.  IL-10 production by CD4+ effector T cells: a mechanism for self-regulation , 2010, Mucosal Immunology.

[45]  Giovanna Zinzalla,et al.  Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. , 2009, Future medicinal chemistry.

[46]  C. Dinarello,et al.  Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.

[47]  A. Rudensky,et al.  Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10 , 2007, Nature Immunology.

[48]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[49]  C. Benoist,et al.  Tissue Tregs. , 2016, Annual review of immunology.

[50]  J. Goldberg,et al.  High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. , 2015, Blood.